logo

For the Inventor, By the Inventor

Berlin, Germany

Mologen Ag


USPTO Granted Patents = 15



Trademarks = 1

Forward Citations = 68

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Burghardt Wittig (10 out of 13 patents)

silverMedal Manuel Schmidt (9 out of 11 patents)

bronzeMedal Matthias Schroff (8 out of 12 patents)

4.  Kerstin Kapp (4 out of 6 patents)

5.  Alfredo Zurlo (2 out of 4 patents)

6.  Tomislav Dobric (2 out of 2 patents)

7.  Detlef Oswald (2 out of 2 patents)

8.  Laura Fuertes-López (2 out of 2 patents)

9.  Marcos Timón-Jiménez (2 out of 2 patents)

10.  Christiane Juhls (2 out of 2 patents)

11.  Claas Junghans (2 out of 6 patents)

12.  Christiane Kleuss (1 out of 1 patent)

13.  Janine Loehr (1 out of 1 patent)

14.  Dennis Kobelt (1 out of 1 patent)

15.  Heribert Bohlen (1 out of 3 patents)


15 patents:

1. 10604760 - Combination comprising immunostimulatory oligonucleotides (2020-03-31),
2. 10487333 - Combination comprising immunostimulatory oligonucleotides (2019-11-26),
3. 10280424 - Covalently closed non-coding immunomodulatory DNA construct (2019-05-07),
4. 10006032 - Predictive biomarker for cancer therapy (2018-06-26),
5. 9499815 - Multimer for immunostimulation (2016-11-22),
6. 9375435 - Use of a DNA expression construct (2016-06-28),
7. 9345754 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine (2016-05-24),
8. 9212366 - Immune modulating oligonucleotides in connection with chemotherapeutic measures (2015-12-15),
9. 9012620 - DNA constructs for specific inhibition of gene expression by RNA interference (2015-04-21),
10. 8669100 - [object Object] (2014-03-11),
11. 8017591 - Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals (2011-09-13),
12. 7915035 - Vaccine against oncovirus infections such as infections by feline leukosis virus of the cat (2011-03-29),
13. 7795406 - Agent for treating leishmania infections (2010-09-14),
14. 7635468 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine (2009-12-22),
15. 7074772 - Design principle for the construction of expression constructs for gene therapy (2006-07-11),
Mologen AG is a biopharmaceutical company engaged in the research and development of immunotherapies for the treatment of cancer and infectious diseases. With a focus on immunomodulators and DNA-based TLR9 agonists, Mologen aims to provide innovative and effective therapeutic solutions. The company's pipeline includes product candidates such as lefitolimod, an immune checkpoint inhibitor, and EnanDIM, a next-generation DNA-based TLR9 agonist. Mologen AG is committed to advancing the field of immunotherapy and improving patient outcomes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

15 Patents

#63 in D-1000 Berlin

#2,773 in Germany

#38,727 in the World

...
Berlin, Germany

Mologen Ag

Forward Citations = 68

20 inventors:

goldMedal Burghardt Wittig (10 out of 13 patents)

silverMedal Manuel Schmidt (9 out of 11 patents)

bronzeMedal Matthias Schroff (8 out of 12 patents)

4.  Kerstin Kapp (4 out of 6 patents)

5.  Alfredo Zurlo (2 out of 4 patents)

Please report any incorrect information to support@idiyas.com
Loading…